# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Frédéric Chopin (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI020-SYN-TD
- Date: 1838-05-15
- Fictional facility: St. Posthumous Health Center
- Fictional author: Matthias Lindqvist, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

End of the eight-week intensive phase. **S**

## History of present illness

Mr. Chopin completed the 56 doses of the intensive phase yesterday, all observed by video within eight weeks, and pyrazinamide has stopped; from today he takes rifapentine, moxifloxacin, isoniazid, and pyridoxine for nine more weeks. The isolate is susceptible to rifampin, isoniazid, pyrazinamide, and moxifloxacin. The cultures from the third week show no growth at six weeks. His cough has gone except for a little phlegm on waking, and he has gained 3.5 kg since diagnosis. He has no tendon pain, tingling, yellowing, or rash. He is teaching twelve students a week and has told them about his illness; none has left. The health department tells him the investigation of his contacts is going well, without giving him details. **S**

| Element | Detail |
|---|---|
| Treatment | 56 of 56 intensive-phase doses observed; continuation phase from today |
| Susceptibility | Susceptible to rifampin, isoniazid, pyrazinamide, and moxifloxacin |
| Cultures | Third-week cultures negative at six weeks |
| Weight | 52.0 kg, up 3.5 kg |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | A little phlegm on waking; no cough during the day; no blood |
| Constitutional | Negative | No fever or night sweats; appetite good |
| Musculoskeletal | Negative | No tendon pain |
| Neurological | Negative | No numbness or tingling |
| Psychiatric | Negative | Mood good; PHQ-9 4; no thoughts of suicide or self-harm |

5 systems reviewed. **S**

## Current medications

- Rifapentine 150 mg tablets, eight tablets (1200 mg) daily with food **S**
- Moxifloxacin 400 mg tablet, one tablet daily **S**
- Isoniazid 300 mg tablet, one tablet daily **S**
- Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 108/68 mmHg; pulse 78 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 98% on room air; weight 52 kg; BMI 18 kg/m². All vital signs are synthetic.

ALT: 29 U/L; AST: 27 U/L; Total bilirubin: 0.6 mg/dL; Hemoglobin: 13 g/dL (low); PHQ-9: 4. All results are synthetic.

## Change since baseline

- ALT: 18 U/L at baseline, 29 U/L at this visit **S**
- AST: 24 U/L at baseline, 27 U/L at this visit **S**
- Total bilirubin: 0.5 mg/dL at baseline, 0.6 mg/dL at this visit **S**
- Hemoglobin: 12.1 g/dL (low) at baseline, 13 g/dL (low) at this visit **S**
- PHQ-9: 7 at baseline, 4 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 52.0 kg |
| Eyes | No icterus |
| Respiratory | Clear apart from a few fine crackles at the right apex |
| Musculoskeletal | Tendons non-tender |
| Neurological | Normal sensation in the fingers and feet |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Drug-susceptible pulmonary tuberculosis, continuation phase** (A15.0). Intensive phase completed on time with a full clinical response. Liver tests normal (ALT 29, AST 27, bilirubin 0.6). Hemoglobin 13.0, up from 12.1. Dr. Kowalczyk-Grant reviewed the results by message and agrees with continuing. **S**
   - Rifapentine 1200 mg, moxifloxacin 400 mg, isoniazid 300 mg, and pyridoxine daily by video for 63 doses.
   - Two-month sputum smear and culture today, from the morning sample.
2. **Moderate protein-calorie malnutrition** (E44.0). Improving: BMI 18.0. **S**
   - Continue the supplements until his weight reaches 55 kg.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Symptom review: cough, sputum, hemoptysis, fever, night sweats | Every visit | Completed today | Morning phlegm only |
| Examination | Weight, with the pyrazinamide dose checked against the weight band | Monthly | Completed today | 52.0 kg; pyrazinamide finished within its band |
| Medication safety | Adverse effects: hepatitis symptoms, tendon pain, numbness or tingling, rash, nausea, orange body fluids | Every visit | Completed today | None |
| Laboratory | Liver tests (ALT, AST, bilirubin) | Baseline; repeat for symptoms or risk factors (here at two to three weeks, for low weight and albumin) | Completed today | ALT 29, AST 27 U/L, bilirubin 0.6 mg/dL, all normal |
| Laboratory | Hemoglobin | When low at baseline | Completed today | 13.0 g/dL, up from 12.1; anemia of inflammation resolving |
| Laboratory | Phenotypic susceptibility (rifampin, isoniazid, pyrazinamide, moxifloxacin) | At baseline | Completed today | Susceptible to rifampin, isoniazid, pyrazinamide, and moxifloxacin |
| Laboratory | Sputum acid-fast smear and culture | Baseline, then monthly until two consecutive cultures are negative | Completed today | Third-week cultures: no growth at six weeks (first negative culture) |
| Laboratory | Two-month sputum culture | At the end of the intensive phase; a positive result needs evaluation and repeat susceptibility testing | Completed today | Smear negative today; culture sent |
| Imaging | Chest X-ray | Baseline; at two months only if baseline cultures were negative; end of treatment optional | Not indicated | Not needed at two months, because the baseline cultures were positive |
| Medication safety | Doses observed and the completion clock (56 doses within 70 days, 63 within 84 days, 119 within five months) | Every visit | Completed today | 56 doses in 56 days, within the 70-day limit |
| Referral | Contact investigation (students, friends, close contacts) | Led by the health department from diagnosis | Referred | Continuing with the health department; no results in his record |
| Survey | Depression screen (PHQ-9) | At diagnosis, at two months, and at the end of treatment | Completed today | 4, item 9 scored 0 |
| Self-management | Nutrition: dietitian, intake, supplement drinks | Every visit until weight is restored | Completed today | Supplements continue; eating well |
| Referral | Infectious diseases review | At diagnosis, at two months, and at the end of treatment | Completed today | Results reviewed by message today |

## Goal progress

- Complete all 119 doses within five months by video-observed therapy. In progress; target 1838-07-21. **S**
- Sputum culture negative at two months. In progress; target 1838-07-21. **S**
- Return to teaching once the health department confirms he is no longer infectious. Outcome by 1838-04-07: Released from isolation after three negative smears and more than two weeks of treatment; teaching again from the third week. **S**
- Weight back to at least 55 kg by the end of treatment. In progress; target 1838-07-21. **S**
- PHQ-9 below 5 by the end of treatment. In progress; target 1838-07-21. **S**

## Guideline basis

- Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016), American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America (Clinical Infectious Diseases)
- Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022 (2022), Centers for Disease Control and Prevention (MMWR)
- An official ATS statement: hepatotoxicity of antituberculosis therapy (2006), American Thoracic Society (American Journal of Respiratory and Critical Care Medicine)
- Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition) (2012), Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition (JPEN)
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- End-of-treatment visit after the 119th dose. Call the same day for hepatitis symptoms, tendon pain, or a returning cough. **S**
- Next scheduled visit 1838-07-21: end-of-treatment review after 119 doses. **S**
